Literature DB >> 31356361

Essential elements of an outpatient total joint replacement programme.

Jinlei Li1, Lee E Rubin2, Edward R Mariano3.   

Abstract

PURPOSE OF REVIEW: To summarize the safety and feasibility of outpatient total joint arthroplasty (TJA) from the perspectives of short-term complications, long-term functional outcomes, patient satisfaction and financial impact, and to provide evidence-based guidance on how to establish an outpatient TJA programme. RECENT
FINDINGS: TJA has been recently transitioned from an exclusively inpatient procedure for all Medicare and Medicaid patients to an outpatient surgery in properly selected total knee arthroplasty patients. This change may decrease costs while maintaining comparable rates of readmission, adverse events, positive surgical outcomes and patient satisfaction.
SUMMARY: With a standardized clinical pathway, outpatient TJA can be safe and effective in a subset of patients. Essential components of a successful outpatient TJA programme include proper patient selection, preoperative patient/family education, perioperative multidisciplinary coordination and opioid-sparing analgesia, and early and effective postdischarge planning. More studies are needed to further assess and optimize this new care paradigm.

Entities:  

Year:  2019        PMID: 31356361     DOI: 10.1097/ACO.0000000000000774

Source DB:  PubMed          Journal:  Curr Opin Anaesthesiol        ISSN: 0952-7907            Impact factor:   2.706


  2 in total

1.  First Reported Series of Outpatient Total Knee Arthroplasty in the Middle East.

Authors:  Muthana M Sartawi; Hafizur Rahman; James M Kohlmann; Brett R Levine
Journal:  Arthroplast Today       Date:  2020-09-15

2.  Neuraxial and general anesthesia for outpatient total joint arthroplasty result in similarly low rates of major perioperative complications: a multicentered cohort study.

Authors:  Edward Yap; Julia Wei; Christopher Webb; Kevin Ng; Matthias Behrends
Journal:  Reg Anesth Pain Med       Date:  2022-01-06       Impact factor: 6.288

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.